Cargando…
HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM
INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607595/ https://www.ncbi.nlm.nih.gov/pubmed/33132213 http://dx.doi.org/10.1136/bmjdrc-2020-001751 |
_version_ | 1783604671542198272 |
---|---|
author | Bozkurt, Latife Göbl, Christian S Leitner, Karoline Pacini, Giovanni Kautzky-Willer, Alexandra |
author_facet | Bozkurt, Latife Göbl, Christian S Leitner, Karoline Pacini, Giovanni Kautzky-Willer, Alexandra |
author_sort | Bozkurt, Latife |
collection | PubMed |
description | INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological precursors of glucose intolerance in early pregnancy that characterize women who develop gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: 220 pregnant women underwent an HbA1c measurement as well as an oral glucose tolerance test (OGTT) with multiple measurements of glucose, insulin and C-peptide for evaluation of insulin sensitivity and beta-cell function at 16th gestational week (IQR: 14–18). Clinical follow-ups were performed until end of pregnancy. RESULTS: Increased maternal HbA1c ≥5.7% (39 mmol/mol) corresponding to pre-diabetes outside of pregnancy was associated with altered glucose dynamics during the OGTT. Pregnancies with early HbA1c ≥5.7% showed higher fasting (90.4±13.2 vs 79.7±7.2 mg/dL, p<0.001), mean (145.6±31.4 vs 116.2±21.4 mg/dL, p<0.001) as well as maximum glucose concentrations and tended to a delay in reaching the maximum glucose level compared with those with normal-range HbA1c (186.5±42.6 vs 147.8±30.1 mg/dL, p<0.001). Women with increased HbA1c showed impaired beta-cell function and differences in disposition index independent of body mass index status. We observed a high specificity for the HbA1c cut-off of 5.7% for GDM manifestation (0.96, 95% CI 0.91 to 0.98) or need of glucose-lowering medication (0.95, 95% CI 0.90 to 0.98) although overall predictive accuracy was moderate to fair. Further, elevated HbA1c was associated with higher risk for delivering large-for-gestational-age infants, also after adjustment for GDM status (OR 4.4, 95% CI 1.2 to 15.0, p=0.018). CONCLUSIONS: HbA1c measured before recommended routine screening period reflects early pathophysiological derangements in beta-cell function and glucose disposal that are characteristic of GDM development and may be useful in early risk stratification. |
format | Online Article Text |
id | pubmed-7607595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-76075952020-11-12 HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM Bozkurt, Latife Göbl, Christian S Leitner, Karoline Pacini, Giovanni Kautzky-Willer, Alexandra BMJ Open Diabetes Res Care Cardiovascular and Metabolic Risk INTRODUCTION: It is of current interest to assess eligibility of hemoglobin A1c (HbA1c) as a screening tool for earlier identification of women with risk for more severe hyperglycemia in pregnancy but data regarding accuracy are controversial. We aimed to evaluate if HbA1c mirrors pathophysiological precursors of glucose intolerance in early pregnancy that characterize women who develop gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS: 220 pregnant women underwent an HbA1c measurement as well as an oral glucose tolerance test (OGTT) with multiple measurements of glucose, insulin and C-peptide for evaluation of insulin sensitivity and beta-cell function at 16th gestational week (IQR: 14–18). Clinical follow-ups were performed until end of pregnancy. RESULTS: Increased maternal HbA1c ≥5.7% (39 mmol/mol) corresponding to pre-diabetes outside of pregnancy was associated with altered glucose dynamics during the OGTT. Pregnancies with early HbA1c ≥5.7% showed higher fasting (90.4±13.2 vs 79.7±7.2 mg/dL, p<0.001), mean (145.6±31.4 vs 116.2±21.4 mg/dL, p<0.001) as well as maximum glucose concentrations and tended to a delay in reaching the maximum glucose level compared with those with normal-range HbA1c (186.5±42.6 vs 147.8±30.1 mg/dL, p<0.001). Women with increased HbA1c showed impaired beta-cell function and differences in disposition index independent of body mass index status. We observed a high specificity for the HbA1c cut-off of 5.7% for GDM manifestation (0.96, 95% CI 0.91 to 0.98) or need of glucose-lowering medication (0.95, 95% CI 0.90 to 0.98) although overall predictive accuracy was moderate to fair. Further, elevated HbA1c was associated with higher risk for delivering large-for-gestational-age infants, also after adjustment for GDM status (OR 4.4, 95% CI 1.2 to 15.0, p=0.018). CONCLUSIONS: HbA1c measured before recommended routine screening period reflects early pathophysiological derangements in beta-cell function and glucose disposal that are characteristic of GDM development and may be useful in early risk stratification. BMJ Publishing Group 2020-11-01 /pmc/articles/PMC7607595/ /pubmed/33132213 http://dx.doi.org/10.1136/bmjdrc-2020-001751 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Cardiovascular and Metabolic Risk Bozkurt, Latife Göbl, Christian S Leitner, Karoline Pacini, Giovanni Kautzky-Willer, Alexandra HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title | HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title_full | HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title_fullStr | HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title_full_unstemmed | HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title_short | HbA1c during early pregnancy reflects beta-cell dysfunction in women developing GDM |
title_sort | hba1c during early pregnancy reflects beta-cell dysfunction in women developing gdm |
topic | Cardiovascular and Metabolic Risk |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607595/ https://www.ncbi.nlm.nih.gov/pubmed/33132213 http://dx.doi.org/10.1136/bmjdrc-2020-001751 |
work_keys_str_mv | AT bozkurtlatife hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm AT goblchristians hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm AT leitnerkaroline hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm AT pacinigiovanni hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm AT kautzkywilleralexandra hba1cduringearlypregnancyreflectsbetacelldysfunctioninwomendevelopinggdm |